Selected from 230+ global submissions, we’ve been recognised by the world’s leading healthcare trade fair for bringing earlier, explainable sepsis detection to real clinical workflows.
We’re proud to share that Aisthesis Medical has been named one of the Top 15 Medical Start-Ups of 2025 by the MEDICA Start-Up Competition — selected in the highly competitive AI in Healthcare track, from a global field of more than 230 submissions.
MEDICA isn’t just any trade fair. It’s the world’s largest international event for the medical sector — where the innovations that shape the next decade of healthcare get their first major stage. Being named among the top 15 is a meaningful external signal that VIOSync is solving a real problem, in the right way, at the right time.
What the Recognition Represents
The MEDICA Innovation Forum Start-Up Competition evaluates companies at the intersection of clinical relevance, technological maturity, and real-world applicability. The AI in Healthcare track, in particular, draws submissions from across Europe, North America, and beyond — all competing to demonstrate that their solution isn’t just technically impressive, but clinically meaningful.
Being selected in that field is validation that VIOSync — our AI-driven platform for early sepsis detection and acute deterioration management — is being recognised not just by clinicians and hospital partners, but by the global healthcare innovation community.
What We Showcased at the MEDICA Innovation Forum
On 18 November 2025, from 15:00–17:00 CET in Hall 12, we demonstrated VIOSync live to attendees at the MEDICA Innovation Forum. The session focused on three core capabilities that set VIOSync apart:
- Earlier detection: Sepsis risk prediction up to 48 hours in advance, giving clinical teams a window to act before deterioration becomes critical.
- Explainable AI (XAI): Transparent, clinician-readable outputs that support trust, validation, and regulatory auditability — not a black box.
- Real workflow integration: Evidence-based guidance embedded directly into how clinical teams already work — reducing friction at the bedside, not adding to it.
The conversations at MEDICA reinforced something we hear consistently from clinical partners: the next wave of acute care AI won’t be won by the most technically sophisticated algorithm. It’ll be won by the solution that earns trust on the ward — and that’s what VIOSync is designed to do.
Why Sepsis — and Why Now
Sepsis remains one of the leading causes of preventable death in hospitals worldwide. Despite growing awareness, detection still happens too late — when the clinical picture is already obvious and the window to prevent organ dysfunction is closing.
The recognition at MEDICA reflects a broader shift in how the healthcare sector is thinking about this problem. The question is no longer whether AI can help — it’s which AI solutions are actually ready to be deployed safely, transparently, and at scale.
We believe VIOSync answers that question. And being named a Top 15 Medical Start-Up of 2025 at MEDICA is one of the strongest external signals yet that the wider healthcare community agrees.
What’s Next for Aisthesis Medical
MEDICA was a milestone — but the journey continues. We’re heading into 2026 with strong momentum, including our upcoming appearance at Tech Tour AI for Health 2026 in Bochum on 12–13 March, where VIOSync will be showcased alongside Europe’s leading clinical AI innovators.
We’re actively exploring clinical collaborations, NHS and hospital partnerships, and investment discussions with organisations that share our conviction that earlier sepsis detection saves lives.
About Aisthesis Medical
Aisthesis Medical is a deep-tech medtech startup developing cutting-edge AI-driven solutions to revolutionize acute care. Founded in 2022, our mission is to save lives by predicting and preventing sepsis before it becomes fatal. Aisthesis Medical is revolutionizing acute care with VIOSync, the first holistic AI-driven sepsis care platform that goes beyond early prediction to guide clinical intervention and optimize patient outcomes. VIOSync, predicts sepsis up to 48 hours earlier, integrates directly into hospital workflows, and optimizes treatment pathways to reduce unnecessary antibiotic use.
Ready to Learn More?
Whether you’re a hospital system, NHS trust, healthcare investor, or clinical collaborator — we’d love to connect and share what’s next for VIOSync.
📩 Get in touch: https://aisthesismed.com/contact/
🌐 Learn more about VIOSync: https://aisthesismed.com/product/